Atomoxetine treatment of attention-deficit/hyperactivity disorder

Objective: To review the literature of the first nonstimulant approved for treatment of attention-deficit/hyperactivity disorder (ADHD). Data Sources: Primary literature and review articles were obtained through PubMed/MEDLINE (1966-February 2003). Study Selection and Data Extraction: Literature evaluating atomoxetine in ADHD was selected. Animal data were excluded. Data Synthesis: Stimulants are currently first-line therapy for ADHD. However, their use raises several concerns including the potential for abuse and adverse effects. Atomoxetine introduces a new therapeutic drug class, selective norepinephrine-reuptake inhibitors, for ADHD management. This additional treatment option offers potential advantages over current therapies. Conclusions: Clinical trials demonstrate that atomoxetine is a safe and effective alternative for ADHD treatment in children and adults; however, its disadvantages may hinder it from becoming a first-line agent.